CPRX News and Press, Catalyst Pharmaceuticals Inc. From 05/09/24

2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...

2024-05-09 10:52:07 ET Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Conference Call May 9, 2024 8:30 a.m. ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Comm...

2024-05-08 16:47:36 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade) Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Catalyst Pharmaceuticals Q1 2024 Earnings Preview ...

Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE&...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-07 17:20:35 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade) Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Citi starts Catalyst at buy, cites rare disease drug port...

CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-t...

2024-04-23 10:29:06 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Edgewise Therapeutics Historical earnings data for Edg...

CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients livin...

2024-04-06 07:52:16 ET Summary Catalyst Pharmaceuticals' stock has performed well, up approximately 20% since my previous article's tepid "Buy" rating. Its stock price is no longer depressed, and its guidance for 2024 is unremarkable, leading to a downgrading to a "Hold". Acqu...